Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech

03/11/2015 - 1 minute

This is the third interview we publish from BIO (yes, we are working hard). It comes after the interview of Simon Moroney, CEO of MorphoSys and Jane Dancer, CBO of F-star.

medigene-logo-frontMedigene is another big/famous Biotech company of Munich, Germany. It was founded over 20 years ago and is now specialised in cell-based therapies. It counts roughly 70 employees and has a market cap of 150 million euros. Peter Llewellyn-Davies has previously worked as CFO of Wilex AG and been in the board of ImmunoCore (the UK Biotech which raised $330 million in a private round!!)

It was very exciting to meet Peter and interviewing him on Medigene’s dendritic cells vaccines, its TCR program as well as its financial situation.

Check it out:

Please accept preferences cookies to watch this video.

Bonus – Medigene did a great animation video on how its TCR works. Worth checking out too:

Please accept preferences cookies to watch this video.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member